Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The lead anorexia nervosa program has completed formulation and pre‑clinical work demonstrating safety and effective delivery via buccal film without first‑pass metabolism and is moving into an investigator‑initiated open‑label Phase II trial of psilocybin‑assisted psychotherapy in anorexia nervosa in Israel, with company-sponsored Phase I/IIa planned around 2023–2024.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Short Wave Pharma.